Zacks: Analysts Anticipate SOPHiA GENETICS SA (NASDAQ:SOPH) Will Announce Quarterly Sales of $11.01 Million

Equities analysts expect SOPHiA GENETICS SA (NASDAQ:SOPHGet Rating) to announce $11.01 million in sales for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for SOPHiA GENETICS’s earnings, with estimates ranging from $10.68 million to $11.45 million. The business is scheduled to issue its next earnings results before the market opens on Monday, January 1st.

On average, analysts expect that SOPHiA GENETICS will report full year sales of $52.49 million for the current financial year, with estimates ranging from $51.70 million to $52.90 million. For the next fiscal year, analysts forecast that the firm will post sales of $74.68 million, with estimates ranging from $71.72 million to $77.64 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that cover SOPHiA GENETICS.

SOPHiA GENETICS (NASDAQ:SOPHGet Rating) last released its quarterly earnings data on Tuesday, March 15th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.01. SOPHiA GENETICS had a negative return on equity of 39.82% and a negative net margin of 182.14%. The business had revenue of $10.94 million during the quarter, compared to analysts’ expectations of $11.27 million.

SOPH has been the subject of several research analyst reports. Morgan Stanley dropped their price objective on SOPHiA GENETICS from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, March 16th. Zacks Investment Research upgraded SOPHiA GENETICS from a “sell” rating to a “hold” rating in a research note on Wednesday, March 16th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $20.67.

A number of hedge funds have recently bought and sold shares of SOPH. Generation Investment Management LLP bought a new position in SOPHiA GENETICS during the 3rd quarter valued at approximately $121,099,000. Credit Suisse AG bought a new position in SOPHiA GENETICS during the 3rd quarter valued at approximately $32,998,000. Principal Financial Group Inc. bought a new position in SOPHiA GENETICS during the 3rd quarter valued at approximately $14,418,000. Jennison Associates LLC increased its position in SOPHiA GENETICS by 123.4% during the 4th quarter. Jennison Associates LLC now owns 1,441,590 shares of the company’s stock valued at $20,326,000 after buying an additional 796,173 shares in the last quarter. Finally, Pura Vida Investments LLC bought a new position in SOPHiA GENETICS during the 3rd quarter valued at approximately $7,889,000. 29.08% of the stock is owned by institutional investors.

NASDAQ SOPH opened at $7.00 on Friday. SOPHiA GENETICS has a fifty-two week low of $6.26 and a fifty-two week high of $19.80. The stock has a 50 day simple moving average of $9.64 and a two-hundred day simple moving average of $12.57.

SOPHiA GENETICS Company Profile (Get Rating)

SOPHiA GENETICS SA operates as a healthcare technology company. The company offers SOPHiA DDM platform, a cloud-based software-as-a-service platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, products, and services are used by hospital, laboratory, and biopharma worldwide.

Further Reading

Get a free copy of the Zacks research report on SOPHiA GENETICS (SOPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for SOPHiA GENETICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SOPHiA GENETICS and related companies with MarketBeat.com's FREE daily email newsletter.